In the early years of the current millennium, the evidence that BRCA1/2-mutant cells could be sensitive to PARP inhibitors (PARPis) emerged and paved the way for new therapeutic opportunities in different tumors, including BC [3,4,5,6]. This evidence concerns the gene BRCA1 and breast cancer.